Last 12 months
Inside the activity.
0 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 17 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 23 |
| May 2026 | 0 | 15 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 41 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2020 Filed Sep 23, 2020 01:15 UTC |
Dube Eric MDirector · Chief Executive Officer
|
SaleCommon Stock | 9,240 | $19.28 | $178,133.34 |
DisclosureSEC source: 0001209191-20-051611 · doc4.xml · nonDerivative · entry 3 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,260 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:20 UTC |
Rosenberg Noah L.Chief Medical Officer
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051614 · doc4.xml · nonDerivative · entry 1 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,055 F1 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:20 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051615 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,086 F1 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. F2 · balance_after: Includes 592 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:18 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051613 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,431 F1 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:18 UTC |
Clague LauraChief Financial Officer
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051612 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,473 F1 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:15 UTC |
Dube Eric MDirector · Chief Executive Officer
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051611 · doc4.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,500 F2 · kind: On May 9, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 6,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
| September 18, 2020 Filed Sep 23, 2020 01:15 UTC |
Dube Eric MDirector · Chief Executive Officer
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-051611 · doc4.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 F1 · kind: On January 4, 2019, the reporting person was granted performance restricted stock units (PRSUs) covering 50,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 18, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 280 patients in the sparsentan PROTECT Phase 3 Study had been enrolled. Read SEC document |
| August 05, 2020 Filed Aug 6, 2020 20:07 UTC |
ASELAGE STEVEDirector
|
SaleCommon Stock | 2,500 | $19.68 | $49,200.00 |
DisclosureSEC source: 0001209191-20-045456 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,232 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 28, 2020 Filed Jul 30, 2020 23:48 UTC |
Rosenberg Noah L.Chief Medical Officer
|
SaleCommon Stock | 870 | $20.49 | $17,826.30 |
DisclosureSEC source: 0001209191-20-044098 · doc4.xml · nonDerivative · entry 1 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,055 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 197 shares of the Issuer's common stock acquired by the reporting person on May 31, 2020 pursuant to an employee stock purchase program. Read SEC document |
| June 25, 2020 Filed Jun 30, 2020 01:02 UTC |
ASELAGE STEVEDirector
|
SaleCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001209191-20-039338 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,732 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
LYONS GARY ADirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030747 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
LYONS GARY ADirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030747 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Orwin John ADirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030749 · doc4.xml · derivative · entry 2 Orwin John A · CIK 0001477384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Orwin John ADirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030749 · doc4.xml · nonDerivative · entry 1 Orwin John A · CIK 0001477384 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Squarer RonDirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030750 · doc4.xml · derivative · entry 2 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Squarer RonDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030750 · doc4.xml · nonDerivative · entry 1 Squarer Ron · CIK 0001454001 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Meckler Jeffrey ADirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030748 · doc4.xml · derivative · entry 2 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Meckler Jeffrey ADirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030748 · doc4.xml · nonDerivative · entry 1 Meckler Jeffrey A · CIK 0001506916 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Coughlin TimothyDirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030746 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Coughlin TimothyDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030746 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Poole SandraDirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030745 · doc4.xml · derivative · entry 2 Poole Sandra · CIK 0001619622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Poole SandraDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030745 · doc4.xml · nonDerivative · entry 1 Poole Sandra · CIK 0001619622 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
ASELAGE STEVEDirector
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030744 · doc4.xml · derivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
ASELAGE STEVEDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030744 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,732 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Baynes Roy D.Director
|
GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030743 · doc4.xml · derivative · entry 2 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC |
Baynes Roy D.Director
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030743 · doc4.xml · nonDerivative · entry 1 Baynes Roy D. · CIK 0001680739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| May 14, 2020 Filed May 15, 2020 00:59 UTC |
ASELAGE STEVEDirector
|
SaleCommon Stock | 3,062 | $15.09 | $46,205.58 |
DisclosureSEC source: 0001209191-20-029410 · doc4.xml · nonDerivative · entry 3 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,732 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 13, 2020 Filed May 15, 2020 00:59 UTC |
ASELAGE STEVEDirector
|
SaleCommon Stock | 4,063 | $16.41 | $66,673.83 |
DisclosureSEC source: 0001209191-20-029410 · doc4.xml · nonDerivative · entry 2 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,794 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 527 | $16.98 | $8,950.73 |
DisclosureSEC source: 0001209191-20-029022 · doc4.xml · nonDerivative · entry 3 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,473 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 1,250 | $17.16 | $21,450.00 |
DisclosureSEC source: 0001209191-20-029022 · doc4.xml · nonDerivative · entry 2 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 527 | $16.98 | $8,950.73 |
DisclosureSEC source: 0001209191-20-029024 · doc4.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,431 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 525 | $17.16 | $9,009.00 |
DisclosureSEC source: 0001209191-20-029024 · doc4.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,958 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 527 | $16.98 | $8,950.73 |
DisclosureSEC source: 0001209191-20-029023 · doc4.xml · nonDerivative · entry 3 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,494 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 812 | $17.16 | $13,933.92 |
DisclosureSEC source: 0001209191-20-029023 · doc4.xml · nonDerivative · entry 2 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,021 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 12, 2020 Filed May 14, 2020 01:00 UTC |
Rosenberg Noah L.Chief Medical Officer
|
SaleCommon Stock | 527 | $16.98 | $8,950.73 |
DisclosureSEC source: 0001209191-20-029021 · doc4.xml · nonDerivative · entry 1 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,728 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:59 UTC |
ASELAGE STEVEDirector
|
SaleCommon Stock | 1,000 | $17.16 | $17,160.00 |
DisclosureSEC source: 0001209191-20-029410 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,857 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:00 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 1,250 | $14.95 | $18,687.50 |
DisclosureSEC source: 0001209191-20-029022 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:00 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 525 | $14.95 | $7,848.75 |
DisclosureSEC source: 0001209191-20-029024 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,483 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 11, 2020 Filed May 14, 2020 01:00 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 813 | $14.95 | $12,154.35 |
DisclosureSEC source: 0001209191-20-029023 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,833 F1 · kind: The sales reported were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 05, 2020 Filed May 6, 2020 20:09 UTC |
ASELAGE STEVEDirector
|
SaleCommon Stock | 2,500 | $15.88 | $39,700.00 |
DisclosureSEC source: 0001209191-20-027448 · doc4.xml · nonDerivative · entry 1 ASELAGE STEVE · CIK 0001221599 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,857 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 01:54 UTC |
Bruhn Suzanne LouiseDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,750 | $0.00 Strike: $15.63 | $0.00 |
DisclosureSEC source: 0001209191-20-024096 · doc4.xml · derivative · entry 2 Bruhn Suzanne Louise · CIK 0001517790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2030-04-07 F1 · derivative.exercise_date: One-third of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 24 equal monthly installments thereafter. Read SEC document |
| April 08, 2020 Filed Apr 10, 2020 01:54 UTC |
Bruhn Suzanne LouiseDirector
|
GrantCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-024096 · doc4.xml · nonDerivative · entry 1 Bruhn Suzanne Louise · CIK 0001517790 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 23:45 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
SaleCommon Stock | 3,250 | $14.87 | $48,327.50 |
DisclosureSEC source: 0001209191-20-018649 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,646 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.855 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 23:44 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
SaleCommon Stock | 3,500 | $15.02 | $52,570.00 |
DisclosureSEC source: 0001209191-20-018648 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,008 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.855 to $15.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 23:43 UTC |
Clague LauraChief Financial Officer
|
SaleCommon Stock | 4,000 | $15.02 | $60,080.00 |
DisclosureSEC source: 0001209191-20-018647 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.855 to $15.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:08 UTC |
ROTE WILLIAM E.Senior Vice President, R&D
|
GrantCommon Stock | 3,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017541 · doc4.xml · nonDerivative · entry 1 ROTE WILLIAM E. · CIK 0001698262 · Senior Vice President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,896 F1 · kind: On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 6,500 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:07 UTC |
REED ELIZABETH ESVP, GC & Corporate Secretary
|
GrantCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017540 · doc4.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · SVP, GC & Corporate Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,508 F1 · kind: On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 7,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:06 UTC |
Clague LauraChief Financial Officer
|
GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017539 · doc4.xml · nonDerivative · entry 1 Clague Laura · CIK 0001388773 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 F1 · kind: On May 10, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 8,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:05 UTC |
Rosenberg Noah L.Chief Medical Officer
|
SaleCommon Stock | 1,790 | $15.36 | $27,487.24 |
DisclosureSEC source: 0001209191-20-017538 · doc4.xml · nonDerivative · entry 2 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,255 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2020 Filed Mar 10, 2020 01:05 UTC |
Rosenberg Noah L.Chief Medical Officer
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-017538 · doc4.xml · nonDerivative · entry 1 Rosenberg Noah L. · CIK 0001579649 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,045 F1 · kind: On July 26, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 10,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled F2 · balance_after: Includes an aggregate of 1,545 shares of the Issuer's common stock acquired by the reporting person on May 31, 2019 and November 30, 2019 pursuant to an employee stock purchase program. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.